Key Record Dates
| ClinicalTrials.gov Identifier: | NCT04082364 |
|---|---|
| Brief Title: | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY) |
| First Submitted : | September 5, 2019 |
| First Submitted that Met QC Criteria : | September 5, 2019 |
| First Posted : | September 9, 2019 |
| Last Update Submitted that Met QC Criteria : | May 13, 2024 |
| Last Update Posted : | May 16, 2024 |